Skip to main content

Table 2 Effectiveness of the trivalent influenza 2011–12 vaccine against influenza A(H3N2) in target group for vaccination by age group, according to the time since vaccination, cycEVA study (weeks 52/2011 – 14/2012), Spain

From: Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011–2012 season in Spain, among population targeted for vaccination

Study population Time since vaccination Cases and controls (N/N) Vaccinated cases and controls (N/N) OR Influenza VE % (95% CI) Trend p valuec
≥65 years 49–88 days 39/17 4/7 Crude 84 (33;96) 0.211
Adjusted 85 (18;97)a
89–127 days 72/24 37/14 Crude 24 (−92;70)
Adjusted 33 (−102;78)a
128–166 days 58/14 23/4 Crude −64 (−487;54)
Adjusted −376 (−4332;49)a
<65 years 39–75 days 104/64 1/4 Crude 85 (−33;98) 0.335
Adjusted 84 (−138;99)b
76–111 days 114/66 11/6 Crude −7 (−203;62)
Adjusted 19 (−149;73)b
112–148 days 113/71 10/11 Crude 47 (−32;79)
Adjusted 58 (−19;86)b
  1. aModel adjusted for age groups (65–75, 76–85, 86–95 and 95–105 years), and week of swabbing. bModel adjusted for age groups (0–4, 5–14, 15–44 and 45–64 years), and week of swabbing. cTest for trend using time since vaccination as continuous.